- NorthStar Medical Radioisotopes has formed a multi-year strategic partnership with the University of Wisconsin School of Medicine and Public Health.
- The collaboration will focus on radiopharmaceutical research, drug development, and workforce training in nuclear medicine.
NorthStar Medical Radioisotopes, LLC has announced a partnership with the University of Wisconsin School of Medicine and Public Health. The agreement, working with the school’s Initiative for Theranostics and Particle Therapy (ITPT), will support research, clinical development, and workforce training in nuclear medicine.
The collaboration will include joint research projects, clinical and translational drug discovery, and contract research and drug development. It also aims to provide structured education opportunities, allowing students to gain real-world experience and strengthening the talent pool for Wisconsin’s nuclear medicine sector.
“We’re thrilled to partner with one of the nation’s leading academic institutions to drive sector innovation and help accelerate new therapies to market.”
Dr. Frank Scholz, CEO at NorthStar
Key objectives of the partnership include leveraging the university’s research infrastructure for radiopharmaceutical drug development, fostering collaborations between NorthStar scientists and ITPT researchers, and supporting workforce development in radiopharmaceuticals and particle therapy.
The partnership officially begins in September 2025, with several initiatives already in progress.
